StockMarketWire.com - FastForward Innovations noted that investee company Juvenescence, which treats aging diseases, had raised $100m from a funding round.

The second and final tranche of the Series B funding was done at at the same $24.70 price per share as the first tranche.

Fastforward said it therefore maintained the implied value of its investment in that company at around $3.2m.


At 1:29pm: [LON:FFWD] Fastforward Innovations Ltd share price was +0.5p at 7.25p



Story provided by StockMarketWire.com